Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 14/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.64 |
| ▸ | FAP | Q12884 | 1/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20302999 | 1.00 | CYP3A4 (0.79) | CYP3A4CYP2D6FAPADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL18492161 | 0.99 | CYP3A4 (0.77) | CYP3A4CYP2D6FAPADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL19603088 | 0.99 | CYP3A4 (0.77) | CYP3A4CYP2D6FAPADORA2AADORA1 | |
| SCHEMBL23932602 | 0.91 | CYP3A4 (0.83) | CYP3A4CYP2D6FAP | |
| SCHEMBL23932601 | 0.91 | CYP3A4 (0.83) | CYP3A4CYP2D6FAP | |
| SCHEMBL19370589 | 0.89 | CYP3A4 (0.72) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL497725 | 0.88 | CYP3A4 (1.00) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL39724 | 0.88 | CYP3A4 (1.00) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL2040329 | 0.88 | CYP3A4 (1.00) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL18894359 | 0.88 | CYP3A4 (1.00) | CYP3A4CYP2D6FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110308-B2 | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds | NUCORION PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| EP-4335496-A2 | PHOSPHOR(N)AMIDATACETAL AND PHOSPH(ON)ATALCETAL COMPOUNDS | NUCORION PHARMACEUTICALS, INC. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-3334743-B1 | ANTIVIRAL BETA-AMINO ACID ESTER PHOSPHODIAMIDE COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11826375-B2 | Phosphinic amide prodrugs of tenofovir | MERCK SHARP & DOHME LLC (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826375-B2 | Phosphinic amide prodrugs of tenofovir | MERCK SHARP & DOHME LLC (US) | 2023-11-28 | — | — | US | disclosed |
| US-11123355-B2 | Antiviral benzyl-amine phosphodiamide compounds | IDENIX PHARMACEUTICALS LLC (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210188887-A1 | PHOSPHOR(N)AMIDATACETAL AND PHOSPH(ON)ATALCETAL COMPOUNDS | NUCORION PHARMACEUTICALS, INC. | 2021-06-24 | — | — | US | disclosed |
| EP-3752511-A1 | PHOSPHOR(N)AMIDATACETAL AND PHOSPH(ON)ATALCETAL COMPOUNDS | NUCORION PHARMACEUTICALS, INC. (US) | 2020-12-23 | — | — | EP | disclosed |
| WO-2020018399-A1 | PHOSPHINIC AMIDE PRODRUGS OF TENOFOVIR | MERCK SHARP & DOHME CORP. (US) | 2020-01-23 | — | — | WO | disclosed |
| EP-3558322-A1 | ANTIVIRAL BENZYL-AMINE PHOSPHODIAMIDE COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018118826-A1 | ANTIVIRAL BENZYL-AMINE PHOSPHODIAMIDE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180065999-A1 | ANTIVIRAL BETA-AMINO ACID ESTER PHOSPHODIAMIDE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20180065999-A1 | ANTIVIRAL BETA-AMINO ACID ESTER PHOSPHODIAMIDE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2018-03-08 | — | — | US | disclosed |
| US-9822138-B2 | Antiviral beta-amino acid ester phosphodiamide compounds | MERCK SHARP & DOHME CORP. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822138-B2 | Antiviral beta-amino acid ester phosphodiamide compounds | MERCK SHARP & DOHME CORP. (US) | 2017-11-21 | — | — | US | disclosed |
| CN-105814068-B | Substituted phosphoramidate derivative, preparation method and application thereof | 四川海思科制药有限公司 | 2017-08-04 | — | — | CN | disclosed |
| US-20170044192-A1 | ANTIVIRAL BETA-AMINO ACID ESTER PHOSPHODIAMIDE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044192-A1 | ANTIVIRAL BETA-AMINO ACID ESTER PHOSPHODIAMIDE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| WO-2017027434-A1 | ANTIVIRAL BETA-AMINO ACID ESTER PHOSPHODIAMIDE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | WO | disclosed |
| CN-105814068-A | Substituted phosphoramidate derivative, preparation method and application thereof | 四川海思科制药有限公司 | 2016-07-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044192-A1 | ANTIVIRAL BETA-AMINO ACID ESTER PHOSPHODIAMIDE COMPOUNDS | POLD1, PEPD, TYMP | CYP3A4 2362/4885CYP2D6 3903/4885FAP 870/4885 |
| US-11123355-B2 | Antiviral benzyl-amine phosphodiamide compounds | TYMP, PNP, POLI | CYP3A4 2278/4885CYP2D6 3727/4885FAP 2312/4885 |
| US-12110308-B2 | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds | PYGL, MTMR1, PTEN | CYP3A4 4189/4885CYP2D6 4779/4885FAP 501/4885 |
| US-20210188887-A1 | PHOSPHOR(N)AMIDATACETAL AND PHOSPH(ON)ATALCETAL COMPOUNDS | PYGL, MTMR1, PTEN | CYP3A4 4062/4885CYP2D6 4623/4885FAP 710/4885 |
| US-20180065999-A1 | ANTIVIRAL BETA-AMINO ACID ESTER PHOSPHODIAMIDE COMPOUNDS | POLD1, PEPD, TYMP | CYP3A4 2362/4885CYP2D6 3903/4885FAP 870/4885 |
| US-11826375-B2 | Phosphinic amide prodrugs of tenofovir | TYMP, PPA1, PNP | CYP3A4 1743/4885CYP2D6 2129/4885FAP 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.